Ross

5 5 0 0

Longevity Biotech Initiates Clinical Neuroinflammation Biomarker Study at the Department of Veterans Affairs to Investigate Immune Related Aspects of Parkinson's Disease With Continued Support From the Michael J. Fox Foundation

Longevity Biotech, Inc. (LBT) is launching a new clinical study to identify specific immune and inflammatory markers that could potentially be used to both diagnose Parkinson’s disease (PD) and stratify patients by stage of disease. The clinical study will be initially…

Longevity Biotech Awarded $225K Phase I SBIR Contract From NHLBI/NIH to Develop 5A apoA-I Mimetic Peptide for Treatment of Severe Asthma

Longevity Biotech Awarded $225K Phase I SBIR Contract From NHLBI/NIH to Develop 5A apoA-I Mimetic Peptide for Treatment of Severe Asthma

Longevity Biotech Inc. (LBT) has been awarded a Phase I SBIR Contract from the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), to further the development of the 5A apoA-I mimetic peptide program…

Longevity Biotech Awarded Grant From National Multiple Sclerosis Society to Evaluate LBT-3627 as a Novel Drug Candidate for Multiple Sclerosis

Longevity Biotech Awarded Grant From National Multiple Sclerosis Society to Evaluate LBT-3627 as a Novel Drug Candidate for Multiple Sclerosis

​​​​​Longevity Biotech, Inc. (LBT) has received an award from the National Multiple Sclerosis Society through Fast Forward, the Society’s commercial research funding program, to evaluate LBT-3627 in preclinical models as a potential disease-modifying therapeutic agent. The program aims to determine…

Longevity Biotech Granted US Patent Covering Hybridtide Platform Technology for Stabilized Peptide Therapeutics

Longevity Biotech, Inc. (LBT) is pleased to announce that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,782,454 covering the company's Hybridtide® platform technology — a revolutionary peptide technology originally developed in the academic laboratory of co-founder…

Longevity Biotech and University of Nebraska Medical Center Awarded Continuing Grant from the Michael J. Fox Foundation for Parkinson’s Research

Longevity Biotech and University of Nebraska Medical Center Awarded Continuing Grant from the Michael J. Fox Foundation for Parkinson’s Research

​​​​​​​​​​​​Longevity Biotech, Inc. (LBT) and the University of Nebraska Medical Center (UNMC) are pleased to announce support by The Michael J. Fox Foundation for Parkinson's Research (MJFF) to develop a novel immune transformative medicine, LBT-3627 to protect against nerve cell…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login